ABUS vs PHM · P/E 5.4, rev $6.2M vs P/E 7.7, rev $17.95B
Arbutus Biopharma Corp (ABUS) versus PulteGroup Inc (PHM) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
PulteGroup Inc (PHM) is a residential construction company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported PHM revenue for 2024-12-31 was $17.95B. Net income was $3.08B. Revenue was up 11.7% from 2023-12-31 to 2024-12-31. PHM currently screens at market cap $21.92B and trailing P/E 7.7.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. PHM currently screens at market cap $21.92B and trailing P/E 7.7.
Not investment advice. Open the ABUS and PHM stock pages for the full models.
Not investment advice.